Last mentioned: Feb 24, 2026
First Approvals
Anticipated first wave of gene therapy approvals under the new streamlined framework.
Framework Formalized
FDA officially announces the 'plausible mechanism' framework for ultra-rare disease therapies.
Draft Guidance Issued
FDA releases draft guidance on using surrogate endpoints for gene therapy accelerated approval.
START Pilot Launch
FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics (START) pilot program.
The FDA has officially introduced a streamlined regulatory pathway for gene therapies, allowing for accelerated approval based on 'plausible mechanisms' and biomarkers rather than traditional clinical outcomes. This landmark shift aims to fast-track treatments for ultra-rare diseases where traditional large-scale clinical trials are statistically impossible.
This page surfaces every story mentioning Center for Biologics Evaluation and Research (CBER) across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Center for Biologics Evaluation and Research (CBER) was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |